In my lifetime, the island nation of Jamaica, which gained its independence from Great Britain in 1962, has been one of the world’s most cannabis-friendly nations, both for locals and for tourists. While technically marijuana, or ganja as they call it in Jamaica, was until recently illegal, in fact marijuana and marijuana smoking was largely ignored by authorities, and one could not get through the airport at either Negril or Kingston without being offered marijuana by several local entrepreneurs, competing for your business.
I know because I accepted the hospitality of these “Welcome Wagon” connections on a couple of occasions, and found the product to be excellent, and the cost was a bargain, at least compared to high-quality home-grown marijuana in the US.
And, of course, Jamaica is home to the Rastafarians, a fascinating and colorful (frequent use of red, yellow and green stripes in their hats and other clothing, the colors from the Ethiopian flag) religion that was started in Jamaica in the 1930s by descendants of African slaves, that celebrates the spiritual use of cannabis and is practiced by an estimated 1,000,000 adherents world-wide.
For many Americans, their first awareness of Jamaica may well have been cultural, when they first heard Bob Marley, a Rastafari musician, songwriter and singer who introduced reggae music and dreadlocks to the world, openly preached the benefits of marijuana smoking, and who became enormously popular in the U.S. and around the world, selling more than 75 million albums. Similarly, Peter Tosh, another reggae music star who first performed with Marley as part of the Wailers, before becoming a successful solo artist (who could ever forget his 1976 “Legalize It” anthem), popularized Rastafarianism, and advocated for marijuana legalization.
Sadly, Marley died of melanoma in 1981 at the age of 36, but his influence and reputation continue to fascinate, even today. The Marley family earlier this year announced that, in conjunction with the Privateer Holding Company from the U.S., they will be offering a new global cannabis brand to be called Marley Natural, featuring “heirloom Jamaican cannabis strains inspired by those Bob Marley enjoyed.” And President Obama, in a state visit to Jamaica in February, made an unscheduled stop at the Bob Marley museum. Obama had earlier, in an interview with MTV, discussed the influence Marley had on him during his youth.
I traveled to Jamaica on two occasions during the 1990s to work with Jamaica NORML to move proposed legalization proposals forward through their parliament. On both occasions, despite a clear majority of legislators wishing to officially legalize ganja, senior government officials became convinced the U.S. would punish Jamaica were it to legalize marijuana, by cutting important aid programs, and the legalization drive was stopped dead in its tracks. They wanted to legalize ganja, but they needed our foreign aid, and the U.S. was more than happy at that time to use the leverage of our aid programs to dismantle their ganja reform efforts.
But all of that leverage ended once states in the U.S. began to push forward with marijuana legalization, without sanctions or punitive responses from the federal government. Seeing that legalization was no longer verboten within the U.S., the Jamaicans realized they now had the freedom to determine their own domestic marijuana policy without fear of U.S. economic retribution.
In late February of this year, the Jamaican Parliament enacted new laws governing ganja, which took effect on July 15, removing criminal penalties for possession of up to two ounces of marijuana, substituting a $5 civil fine with no arrest or criminal record. In addition, households will be permitted to cultivate up to five marijuana plants. The legislation also authorized officials to enact regulations licensing the cultivation and dispensing of medical and industrial cannabis, as well as the right of the Rastafarians to use ganja as a religious sacrament.
While the Parliament has not yet authorized regulations to license commercial growers and recreational dispensaries, most observers expect that will come in the near future. Already they have invited U.S. marijuana tourism by announcing that those from the U.S. who hold medical recommendations will also qualify to obtain up to 2 ounces of medical ganja while they are in Jamaica. Justice Minister Mark Golding described the reforms as “long overdue.”
And to appropriately celebrate the addition of Jamaica to the growing list of countries that have decriminalized the use of marijuana, High Times recently announced they will be holding a World Cannabis Cup in Negril this year, on Nov. 12–15. Now that’s an occasion I would not want to miss.
Yeah, mon! See you in Negril.
Hello NORML supporters!
Have you heard of O.penVAPE?
Founded in 2012 by six dispensary owners and growers, O.penVAPE produces reliable and easy to use vaporizer pens. Their signature “go.pen” is rechargeable, has seven available color options, and comes with a lifetime warranty. The upgraded “go.pen plus” has a more powerful battery, provides a two-second longer puff than the go.pen, and is also backed by a lifetime warranty.
O.penVAPE also offer accessories like chargers, cartridges, and even apparel on their website! They work with Organa Labs to provide organically extracted cannabis oils for their vape pens. Additionally, O.penVAPE is a founding member of the NORML Business Network and is a financial supporter of NORML’s legalization efforts!
So if you’re looking for a great vaporizer pen for a great price, support the NORML Business Network and consider O.penVAPE!
Check out O.penVAPE products on their website: http://www.openvape.com/.
DISCLOSURE: This post is provided as a service of the NORML Business Network, which works to create mutually beneficial partnerships with marijuana-related businesses that seek to use their enterprise as a positive example of corporate social responsibility. O.penVAPE is a proud member of the NORML Business Network. To learn more about our Network partners, or to become a member, please visit here.
Massachusetts Senator Elizabeth Warren, along with seven other Senators, has directed a letter to the Obama administration demanding regulators answer questions specific to the facilitation of research into the medical benefits of marijuana.
Senators acknowledged the need for unbiased research. They wrote, “While the federal government has emphasized research on the potential harms associated with the use of marijuana, there is still very limited research on the potential health benefits of marijuana — despite the fact that millions of Americans are now eligible
by state law to use the drug for medical purposes.”
The Senators applauded a recent decision by the Department of Health and Human Services to eliminate the HHS Public Health Service review process. But they also acknowledged the drawbacks of NIDA’s monopoly on supply of marijuana for research purposes and the need for alternative providers.
Senators also questioned marijuana’s current classification as a Schedule 1 drug under federal law and its classification under international treaties and if the FDA is prepared to call for the reclassification of cannabidiol.
Addressed to the heads of the Department of Health and Human Services (HHS), the Drug Enforcement Administration (DEA), and the Office of National Drug Control Policy, the letter signals to many that medical marijuana is becoming an even more important issue in the political sphere not only to voters but also to their elected officials.
Co-signing the letter with Senator Warren were Senators Barbara Mikulski (D-Md.), Barbara Boxer (D-Calif.), Ron Wyden (D-Ore.), Jeff Merkley (D-Ore.), Kirsten Gillibrand (D-N.Y.), Edward J. Markey (D-Mass.), and Cory Booker (D-N.J.). The Senators are seeking a reply to their questions from the administration by August 31.
Legislation to establish a system of medical dispensaries for the state’s nearly 14,000 medical marijuana patients has become law.
Governor David Ige signed the measure, stating, “I support the establishment of dispensaries to ensure that qualified patients can legally and safely access medical marijuana. We know that our challenge going forward will be to adopt rules that are fair, cost effective and easy to monitor. The bill sets a timeline. We will make a good faith effort to create a fair process that will help the people most in need.”
House Bill 321 permits the state “to issue eight dispensary licenses statewide; provided that three dispensary licenses shall be issued for the city and county of Honolulu, two dispensary licenses each shall be issued for the county of Hawaii and the county of Maui, and one dispensary license shall be issued for the county of Kauai. … Up to two production centers shall be allowed under each dispensary license, provided that each production center shall be limited to no more than three thousand marijuana plants. A dispensary licensee may establish up to two retail dispensing locations under the licensee’s dispensary license.”
The state Department of Health has until January 4, 2016 to finalize rules governing the dispensary program. Licensed dispensaries are anticipated to be operational by July 15, 2016. Once operational, qualified patients will be able to obtain up to four ounces of cannabis or cannabis-infused products, such as oils, tinctures, or lozenges, from a licensed provider every 15 days.
A separate provision included in HB 321 also adds post-traumatic stress as a qualifying condition under the state’s medical cannabis law.
Legislation initially enacted by the legislature in 2000 provides qualified patients the legal right to possess and cultivate cannabis for therapeutic purposes, but did not allow for its production and distribution via dispensaries.
For over 45 years NORML has been at the center of national efforts to legalize responsible use of marijuana by adults. But missing from these efforts was an accurate way to measure impairment. Today we’re happy to announce such a way exists and it’s called Canary.
“Canary is the first app to give consumers the scientific information they need to honestly and accurately evaluate their personal performance, privately, anytime, and anywhere,” says Allen St. Pierre, Executive Director of NORML.
Available for iPhone® and iPad®, Canary combines decades of research and experience, specialized mental and physical performance tests, and sophisticated analysis to accurately measure impairment due to alcohol, medication, fatigue and even the subtle impact of marijuana.
Download and Canary yourself: https://appsto.re/us/QYxB7.i
As a special offer for NORML members, the first 500 downloads of Canary are free. Afterwards the app will be available for $4.99 and a percentage of each sale will go to support responsible consumption initiatives at NORML.
Please try Canary and send us your feedback.
The NORML Team
P.S. For more information about responsible marijuana use visit:
FOR IMMEDIATE RELEASE
Contact: Allen St. Pierre: email@example.com, (202) 483-5500
Organization: National Organization for the Reform of Marijuana Laws (NORML)
Web Site: www.norml.org
iTunes App Store: https://appsto.re/us/QYxB7.i
Additional Contact: Marc Silverman: firstname.lastname@example.org
Canary App Permits Marijuana Consumers To Gauge Their Personal Performance
WASHINGTON, D.C., July 15, 2015. Representatives of the National Organization for the Reform of Marijuana Laws (NORML) today endorsed Canary, the first-ever mobile app that quickly and accurately measures one’s personal performance to determine whether or not a subject may be under the influence of marijuana. Available for iPhone® and iPad®, Canary combines decades of research and experience, specialized mental and physical performance tests, and advanced modeling and analysis to accurately measure behavioral or cognitive impairment. Interested parties may view a full demonstration of the Canary app:
“NORML’s purpose is to influence public opinion to legalize the responsible use of marijuana,” said Allen St. Pierre, Executive Director of NORML. “Canary is the first app to provide consumers with the scientific information they need to accurately evaluate their personal performance, privately, anytime, and anywhere.”
Canary features four distinct mental and physical performance tests, designed to evaluate baseline performance, and then to compare subjects’ behavior against this established baseline. Potential deviation in baseline performance as a result of the use of cannabis, alcohol, prescription drugs, or even exhaustion, is readily identified by the app.
To form this overall picture, Canary uses state-of-the-art metrics and advanced features of the iPhone 4s and later, to measure and record:
- Reaction Time and Divided Attention
- Time Perception
The Canary tests can be completed in two minutes and the results are immediately analyzed to determine the individual user’s performance level. Average performance data from a large group of unintoxicated individuals is used to assess impairment. For greater accuracy, users can set a unique personal baseline; then future tests are measured against this personal baseline.
“Canary is the culmination of 60 years of combined technical and legal experience and thousands of peer-reviewed studies, including NASA, NHTSA, and DOD research, as well as upon thousands of studies specific to cannabis’ acute impact on cognitive and psychomotor functioning,” said Marc Silverman, Canary’s developer. “Canary measures key performance indicators that may be impacted by potentially impairing substances, including marijuana, while respecting users’ privacy. Canary doesn’t share users personal data with anyone.”
“The identification of THC in blood is poorly associated with users’ impairment of performance,” said Leonard Frieling, a published author on the impact of marijuana on functioning and an a ttorney of 39 years. He is also a member of the NORML Legal Committee , Colorado NORML, and (while speaking for himself only) the first Chair of the Colorado Bar Association Marijuana Law Committee. “Canary is the first app to use performance science to help marijuana users consume more responsibly, ” he said. He added: “Of great importance is that Canary is not limited to marijuana’s impact, alcohol’s impact, or any specific cause of behavioral impairment. What we all need to know, on the spot, is ‘are we functioning up to our personal ‘normal’ standards?'”
According to a recent Gallup poll, nearly half of Americans are concerned about how the implementation of statewide marijuana legalization laws may impact traffic safety.
Such concerns pose a potential impediment to the enactment of additional marijuana law reforms. The Canary app seeks to respond to these concerns in a way that utilizes the best available science to assure personal responsibility and safety.
For more information visit: www.mycanaryapp.com
Canary is compatible with iOS 7.1 and iPhone versions 4S and newer.
For more information regarding cannabis and psychomotor performance, please see: http://norml.org/library/driving-and-marijuana.
NORML’s mission is to move public opinion sufficiently to legalize the responsible use of marijuana by responsible adults. NORML’s Principle of Responsible Use state, “The responsible cannabis consumer does not operate a motor vehicle or other dangerous machinery while impaired by cannabis.” To read NORML’s full Principles, visit: http://norml.org/principles/item/principles-of-responsible-cannabis-use-3.